Inflammation in acute coronary syndromes: Mechanisms and clinical implications;La inflamación en los síndromes coronarios agudos: Mecanismos e implicaciones clínicas

Revista Espanola de Cardiologia

Volumn 57, Issue 5, 2004, Pages 433-446

  Angiolillo, Dominick J ^a   Biasucci, Luigi M ^a   Liuzzo, Giovanna ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute coronary syndromes; Atherosclerosis; C reactive protein; Inflammation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CELECOXIB; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLATELET DERIVED GROWTH FACTOR; SEROTONIN; TROPONIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE ACTIVATION; OUTCOMES RESEARCH; PATHOGENESIS; PREDICTION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 2942744604     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061121     Document Type: Review

References (174)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
4. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
5. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.
6. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.
7. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
9. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
10. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
13. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
14. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-5.
15. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321:199-204.
16. Navarro-López F. Bases genéticas de la enfermedad coronaria Rev Esp Cardiol 2002;55:413-31.
17. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
18. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-Reactive Protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
19. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Pre-procedural senim levels of C-Reactive Protein predict early complications and late restenosis following coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
20. Milazzo D, Biasucci LM, Luciani N, Martinelli L, Canosa C, Schiavello R, et al. Elevated levels of C-Reactive Protein before coronary artery bypass graffing predict recurrences of ischemic events. Am J Cardiol 1999;84:459-61.
21. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van de Loo JC. European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factor and the risk of miocardial infarction or sudden death in the patients with angina pectoris. N Engl J Med 1995;332:635-41.
22. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-Reactive Protein levels in unstable coronary artery dispase. FRISC study group. Fragmin during instability in coronary artery disease. Circulation 1997; 96:4204-10.
23. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, et al. Independent prognostic value of elevated C-Reactive Protein in unstable angina. Circulation 1999;100:1958-68.
24. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;89:839-44.
25. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis In Myocardial Infarction. J Am Coll Cardiol 1998;31: 1460-5.
26. Biasucci I.M. C-Reactive protein and secondary prevention of coronary events. Clin Chim Acta 2001;311-49-52.
27. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995;92:3893-7.
28. Hazen SL, Hsu FF, Gaut JP, Crowley JR, Heinecke JW. Modification of proteins and lipids by myeloperoxidase. Methods Enzymol 1999;300:88-105.
29. Dichtl W, Nilsson L, Goncalves I, Ares, MP, Banfi C, Calara, F, et al. Very low-density lipoprotein activates nuclear factor-B in endothelial cells. Circ Res 1999;84:1085-94.
30. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
31. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988;8:348-58.
32. Khoo JC, Miller E, Pin F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992; 12:1258-66.
33. Morel DW, Hessler JR, Chisholm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24:1070-6.
34. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997;96:3264-5.
35. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
36. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344: 254-7.
37. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997;29:366-73.
38. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:1623-9.
39. Hernández-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
40. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-9.
41. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.
42. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens; Res 1995; 18:87-98.
43. Schmidt AM, Yan SD, Wander JL, Wautier JL, Stem D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-97.
44. Sánchez PL, Morinigo JL, Pabon P, Martin F, Piedra I, Palacios IF, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart 2004;90:264-9.
45. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
46. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
47. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337: 230-6.
48. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
49. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9.
50. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
51. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
52. Astrup P, Kjeldsen K, Wanstrup J. Effects of carbon monoxide exposure on the arterial walls. Ann NY Acad Sci 1970; 174:294-300.
53. Astrup P. Carbon monoxide and peripheral artery disease. Scand J Clin Lab Invest 1967;99(Suppl): 193-7.
54. Thomsen HD. Carbon monoxide-induced atherosclerosis in primates. An electron-microscopic study on the coronary arteries of Macaca trus monkeys. Atherosclerosis 1974;20:233-40.
55. Webster WS, Clarkson TB, Lofland HB. Carbon monoxide-aggravated atherosclerosis in the squirrel monkey. Exp Mol Pathol 1970;13:36-50.
56. Sarma JSM, Tillmanns H, Ikeda S, Bing RJ. The effect of carbon monoxide on lipid metabolism of human coronary arteries. Atherosclerosis 1975;22:193-8.
57. Nordskog BK, Blixt AD, Morgan WT, Fields WR, Hellmann GM. Matrix-degrading and pro-inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate. Cardiovasc Toxicol 2003;3:101-17.
58. Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis 2003;45:443-58.
59. Winkelmann BR, Boehm BO, Nauck M, Kleist P, Marz W, Verho NK, et al. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in nondiabetic individuals with coronary artery disease. Curr Med Res Opin 2001;17:132-41.
60. Danesh J, Collins R, Peon R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
61. Kol A, Bourcier T, Lichtman AH, Lippy P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999;103:571-7.
62. Martínez Torres A, Martínez Gaensly M. Helicobacter pytoli: ¿un nuevo factor de riesgo cardiovascular? Rev Esp Cardiol 2002;55:652-6.
63. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23-8.
64. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-90.
65. Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-51.
66. Hajjar DP, Fabricant CG, Minick CR. Fabricant J. Virus-induced atherosclerosis: herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 1986; 122:62-70.
67. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
68. Topper JN, Gimbrone MA Jr. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. Mol Med Today 1999;5:40-6.
69. De Caterina R, Libby, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxidedecreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
70. Li H, Cybulsky MI, Gimbrone MA Jr, Lippy P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler Throm 1993;13:197-204.
71. Cybulsky MI, Iiyama K, Li H,Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-62.
72. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellutar adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 1994;94:885-91.
73. Gu L, Okada Y, Clinton S, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol Cell 1998;2:275-81.
74. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7.
75. Pérez-Fernández R, Kaski JC. Interleucina-10 y enfermedad coronaria. Rev Esp Cardiol 2002;55:738-50.
76. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264-8.
77. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150: 1687-99.
78. Martínez-González J, Llorente-Cortes V, Badinion L. Biología celular y molecular de las lesiones ateroscleró ticas. Rev Esp Cardiol 2001;54:218-31.
79. Wilcoxon JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-43.
80. Leatham EW, Bath PMW, Tose JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995;73:10-3.
81. Bevitacqua MP, Gimbrone MA. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987; 13:425-33.
82. Berberian PA, Myers W, Tytell M, Challa Bond MG. Immunohistochemical localization of heat shock protein 70 in normal appearing and atherosclerotic specimens of human arteries. Am J Pathol 1990;136:71-80.
83. Sambola A, Fuster V, Badimon JJ. Papel de los factores de riesgo en la trombogenicidad sanguínea y los síndromes coronarios agudos. Rev Esp Cardiol 2003;56:1001-9.
84. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, et al. Differential expression of three T-lymphocyte activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999;104:1041-50.
85. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endotelial cell expression of membrane type 1 matrix metalloproteinase. J Biol Chem 1999;274;443-9.
86. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
87. Sukhova GK Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.
88. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104:1899-904.
89. Cianflone D, Ciccirillo F, Buffon A, Trani C, Scabbia EV, Finocchiaro ML, et al. Comparison of coronary angiographic narrowing in stable angina pectoris, unstable angina pectoris, and in acute myocardial infarction. Am J Cardiol 1995;76:215-9.
90. Bogaty P, Brecker SJ, White SE, Stevenson RN, el-Tamimi H, Balcon R, et al. Comparison of coronary angiographic findings in acute and chronic first presentation of ischemic heart disease. Circulation 1993;87:1938-46.
91. Maseri A. Ischemic heart disease. A rational basis for clinical practice and clinical research. New York: Churchill Livingstone, 1995; p. 237-301.
92. Maseri A. The transition from stable to unstable coronary artery disease: a key research target. Ital Heart J 2003;4:345-6.
93. Liuzzo G, Biasucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, et al. Enhanced inflammatory response in patients with pre-infarction unstable angina. J Am Coll Cardiol 1999; 34:1696-703.
94. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
95. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137-40.
96. Baroldi G, Falzi G, Mariani F. Sudden coronary death: a post-mortem study in 208 selected cases compared to 97 « control» subjects. Am Heart J 1979;98:20-31.
97. Kragel AH, Gertz SD, Roberts WC. Morphologic comparison of frequency and types of acute lesions in the major coronary epicardial arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol 1991; 18:801-8.
98. Arbustini E, Grasso M, Diegoli M, Morbini P, Aguzzi A, Fasani R, et al. Coronary thrombosis in non-cardiac death. Cor Art Dis 1993;4:751-9.
99. Davies MJ. Macroscopic or microscopic view of coronary thrombi. Circulation 1990;82(Suppl 3):38-46.
100. Promerance A. Peri-arterial mast cells in coronary atheroma and thrombosis. J Path Bact 1958;76:55-70.
101. Schwartz CJ, Mitchell Jr. Cellular infiltration of the human arterial adventitia associated with atheromatous plaque. Circulation 1962;26:73-8.
102. Gown AM, Tsukada T, Ross R. Human atherosclerosis. Immuno-histochemical analysis of cellular composition of human atherosclerotic lesions. Am J Pathol 1986; 125:191-207.
103. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
104. Sato T, Takebayashi S, Kohchi K. Increased subendothelial infiltration of the coronary arteries with monocytes/macrophages in patients with unstable angina. Atherosclerosis 1987;68:191-7.
105. Khochi K, Takebayashi S, Hikori T, Nobuyoshi M. Significance of adventitial inflammation of the coronary in patients with unstable angina: results at autopsy. Circulation 1985;71:709-16.
106. Wallsh E, Weinstein GS, Franzone A, Clavel A, Rossi PA, Kreps E. Inflammation of the coronary arteries in patients with unstable angina. Texas Heart Institute J 1986;16:105.
107. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. Am J Cardiol 1990;66:562-7.
108. Arbustini E, Grasso M, Diegoli M, Concardi M, Porcu E, Specchia G. Expression of growth factors and oncogene products in human normal and atherosclerotic coronary arteries with and without thrombosis. Pathol Res Pract 1993; 189:637.
109. Flugelman MY, Virmani R, Correa R, Yu ZX, Farb A, Leon MB, et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with non fatal unstable angina. A clue to the mechanism of transformation from stable to the unstable clinical state. Circulation 1993;88:2493-500.
110. Dalen JE, Ockene IS, Alpert JS. Coronary spasm, coronary thrombosis and myocardial infarction: a hypothesis concerning the pathophysiology of acute myocardial infarction. Am Heart J 1982;104:1119-24.
111. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, DeMarchena E, Interian A, Jr, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 1992;326:1451-5.
112. Oshima S, Ogawa H, Yasue H, Okumura K, Matsuyama K, Miyagi H. Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina. J Am Coll Cardiol 1989;14:150-4.
113. Irie T, Imaizumi T, Matuguchi T, Koyanagi S, Kanaide H, Takeshita A, et al. Increased fibrinopeptide A during anginal attacks in patients with variant angina. J Am Coll Cardiol 1989;14:589-94.
114. McFadden EP, Clarke JG, Davies GJ, Haider AW, Kaski JC, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable and variant angina. N Engl J Med 1991;324:648-54.
115. Bertrand ME, La Blanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 1982;65:1299-306.
116. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987;317:1055-9.
117. Maseri A, Crea F. Segmental control of vascular tone in the coronary circulation and pathophysiology of ischemic heart disease. J Appl Cardiovasc Biol 1991;2:163.
118. Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm and coronary vasoconstriction: the case for a distinction. Circulation 1990;81:1983-91.
119. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Chiariello L, et al. Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2001;104:1471-6.
120. Dinerman JL, Mehta JL, Saldeen TG, Emerson S, Wallin R, Davda R, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990;15:1559-63.
121. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996;27:611-6.
122. Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993;88:358-63.
123. Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992;86:790-7.
124. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in «active» coronary artery disease. Am J Cardiol 1990;65:168-72.
125. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and plasma amyloid A protein. Adv Immunol 1983;34:141-212.
126. Monaco C, D'Onofrio G, Rossi E, Milazzo D, Citterio F, Zini G, et al. Neutrophils are activated in acute coronary syndromes but not in severe peripheral vascular disease: a clue for different pathogenetic mechanisms? Circulation 1994;8:1-732.
127. Biasucci LM, Liuzzo G, Caligiuri G, van de Greef W, Quaranta G, Monaco C, et al. Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Am J Cardiol 1996;77:85-7.
128. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996;94:2373-80.
129. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370-6.
130. Collins T, Cybulsky MI. NF-kB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-64.
131. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:E83-8.
132. Monajemi H, Arkenbout EK, Pannekoek H. Gene expression in atherogenesis. Thromb Haemost 2001;86:404-12.
133. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83:4533-7.
134. Oleksowicz L, Mrowiec Z, Isaacs R, Dutcher JP, Puszkin E. Morphologic and ultrastructural evidence of interleukin-6 induced platelet activation. Am J Hematol 1995;48:92-9.
135. Newby AC, Zaltsman AB. Fibrous cap formation or destruction: the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999;41: 345-60.
136. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol 1999;84:J15-20.
137. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 1998;9:413-23.
138. Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994;344:1405-6.
139. Yang ZH, Richard V, Von Segesser L, Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990;82:188-95.
140. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996;97:769-76.
141. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, et al. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 2001;103:2236-41.
142. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-9.
143. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101:2883-8.
144. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-22.
145. Spagnoli LG, Bonanno E, Mauriello A, Palmieri G, Partenzi A, Sangiorgi G, et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J Am Coll Cardiol 2002;40:1579-88.
146. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
147. Caligiuri G, Liuzzo G, Biasucci LM, Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol 1998;32:1295-304.
148. Biasucci LM, Liuzzo G, Ciervo A, Petrucca A, Piro M, Angiolillo DJ, et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003; 107:3015-7.
149. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
150. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
151. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998;81:1405-10.
152. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998;82: 715-9.
153. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000;35: 1535-42.
154. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-47.
155. Morrow DA, Antman EM, Tanasijevic M, Rifai N, De Lemos JA, McCabe CH, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36:1812-7.
156. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from longterm antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29:43-8.
157. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354:1757-62.
158. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 2001;103:2891-6.
159. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-12.
160. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-15.
161. Lenderink T, Boersma E, Heeschen C, Vahanian A, De Boer MJ, Umans V, et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 2003;24:77-85.
162. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
163. Kinlay S, Schwartz GO, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-6.
164. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-66.
165. Lee CW, Chae JK, Lim HY, Hong MK, Kim JJ, Park SW, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999; 138:60-3.
166. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42.
167. Altman R, Scazziota A. Papel de los antiinflamatorios en el tratamiento de los síndromes coronarios agudos. De la ateroinflamación a la aterotrombosis. Rev Esp Cardiol 2003; 56:9-15.
168. Biasucci LM, Liuzzo G, Porto A, Di Giannuario G, Lomaglio D, Piro M, et al. Safety and effectiveness of celecoxib in patients with refractory unstable angina not suitable for revascularization [abstract]. Eur Heart J 2003;4:618.
169. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B. The role of PPARs in atherosclerosis. Trends Mol Med 2002;8:422-30.
170. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998;36:345-9.
171. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;101:2664-9.
172. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954-7.
173. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
174. Kanters E, Pasparakis M, Gijbels MJ, Vergottwe MN, Partouns-Hendriks I, Fijneman RJ, et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;112:1176-85.